Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity. 2005

Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
Instituto de Química Médica (C.S.I.C.), Juan de la Cierva 3, E-28006 Madrid, Spain.

New [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-d-ribofuranosyl]-3'-spiro-5' '-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives substituted at the 4' '-amino group of the spiro moiety with different carbonyl functionalities have been designed and synthesized. Various synthetic procedures, on the scarcely studied reactivity of the 3'-spiroaminooxathioledioxide moiety, have been explored. The compounds were evaluated for their inhibitory effect on both wild-type and TSAO-resistant HIV-1 strains, in cell culture. The presence of a methyl ester (10) or amide groups (12) at the 4''-position conferred the highest anti-HIV-1 activity, while the free oxalyl acid derivative (11) was 10- to 20-fold less active against the virus. In contrast, the presence at this position of (un)substituted ureido or acyl groups markedly diminished or annihilated the anti-HIV-1 activity. Surprisingly, some of the target compounds also showed inhibition of human cytomegalovirus (HCMV) replication at subtoxic concentrations. This has never been observed previously for TSAO derivatives. In particular, compound 26 represents the first TSAO derivative with dual anti-HIV-1 and -HCMV activity.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013141 Spiro Compounds Cyclic compounds that include two rings which share a single atom (usually a carbon). The simplest example of this type of compound is Spiro[2.2]pentane, which looks like a bow tie. Compounds, Spiro
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
November 1994, Journal of medicinal chemistry,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
October 1993, Journal of medicinal chemistry,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
August 2006, Journal of medicinal chemistry,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
August 1992, Journal of medicinal chemistry,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
July 1993, Biochemical pharmacology,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
February 2000, Biochemistry,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
June 2001, Journal of medicinal chemistry,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
June 1992, The Journal of biological chemistry,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
May 1992, Antimicrobial agents and chemotherapy,
Sonia de Castro, and Esther Lobatón, and María-Jesús Pérez-Pérez, and Ana San-Félix, and Alessandra Cordeiro, and Graciela Andrei, and Robert Snoeck, and Erik De Clercq, and Jan Balzarini, and María-José Camarasa, and Sonsoles Velázquez
July 1992, Journal of medicinal chemistry,
Copied contents to your clipboard!